{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T08:26:43Z","timestamp":1775204803850,"version":"3.50.1"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41573-019-0038-z","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T09:16:17Z","timestamp":1567761377000},"page":"169-184","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":368,"title":["Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies"],"prefix":"10.1038","volume":"19","author":[{"given":"Zsolt","family":"Sebestyen","sequence":"first","affiliation":[]},{"given":"Immo","family":"Prinz","sequence":"additional","affiliation":[]},{"given":"Julie","family":"D\u00e9chanet-Merville","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4141-9302","authenticated-orcid":false,"given":"Bruno","family":"Silva-Santos","sequence":"additional","affiliation":[]},{"given":"Jurgen","family":"Kuball","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"38_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-immunol-032713-120216","volume":"32","author":"YH Chien","year":"2014","unstructured":"Chien, Y. H., Meyer, C. & Bonneville, M. Gammadelta T cells: first line of defense and beyond. Annu. Rev. Immunol. 32, 121\u2013155 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"38_CR2","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1126\/science.1063916","volume":"294","author":"M Girardi","year":"2001","unstructured":"Girardi, M. et al. Regulation of cutaneous malignancy by \u03b3\u03b4 T cells. Science 294, 605\u2013609 (2001).","journal-title":"Science"},{"key":"38_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nri3904","volume":"15","author":"B Silva-Santos","year":"2015","unstructured":"Silva-Santos, B., Serre, K. & Norell, H. Gammadelta T cells in cancer. Nat. Rev. Immunol. 15, 683\u2013691 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"38_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1084\/jem.20100269","volume":"208","author":"Y Ma","year":"2011","unstructured":"Ma, Y. et al. Contribution of IL-17-producing \u03b3 \u03b4 T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 208, 491\u2013503 (2011).","journal-title":"J. Exp. Med."},{"key":"38_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.cell.2016.01.002","volume":"164","author":"S Dadi","year":"2016","unstructured":"Dadi, S. et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell 164, 365\u2013377 (2016).","journal-title":"Cell"},{"key":"38_CR6","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.4161\/onci.21659","volume":"1","author":"M Donia","year":"2012","unstructured":"Donia, M., Ellebaek, E., Andersen, M. H., Straten, P. T. & Svane, I. M. Analysis of V\u03b41 T cells in clinical grade melanoma-infiltrating lymphocytes. Oncoimmunology 1, 1297\u20131304 (2012).","journal-title":"Oncoimmunology"},{"key":"38_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1353858","volume":"6","author":"J Wang","year":"2017","unstructured":"Wang, J. et al. Tumor-infiltrating \u03b3\u03b4T cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer. Oncoimmunology 6, e1353858 (2017).","journal-title":"Oncoimmunology"},{"key":"38_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1347742","volume":"6","author":"S Meraviglia","year":"2017","unstructured":"Meraviglia, S. et al. Distinctive features of tumor-infiltrating \u03b3\u03b4 T lymphocytes in human colorectal cancer. Oncoimmunology 6, e1347742 (2017).","journal-title":"Oncoimmunology"},{"key":"38_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.immuni.2014.03.013","volume":"40","author":"P Wu","year":"2014","unstructured":"Wu, P. et al. \u03b3\u03b4T17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity 40, 785\u2013800 (2014).","journal-title":"Immunity"},{"key":"38_CR10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938\u2013945 (2015). This is an excellent but also controversial unbiased description of the immunological landscape of tumour-infiltrating lymphocytes that puts \u03b3\u03b4T cells at the centre of attention. Recommended to be read in combination with Deniger et al.","journal-title":"Nat. Med."},{"key":"38_CR11","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1284723","volume":"6","author":"M Tosolini","year":"2017","unstructured":"Tosolini, M. et al. Assessment of tumor-infiltrating TCR V\u03b39V\u03b42 \u03b3\u03b4 lymphocyte abundance by deconvolution of human cancers microarrays. Oncoimmunology 6, e1284723 (2017). This article presents a critical view of the impact of tumour-infiltrating \u03b3\u03b4T cells on clinical outcomes.","journal-title":"Oncoimmunology"},{"key":"38_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.it.2017.06.004","volume":"38","author":"G Chitadze","year":"2017","unstructured":"Chitadze, G., Oberg, H. H., Wesch, D. & Kabelitz, D. The ambiguous role of \u03b3\u03b4 t lymphocytes in antitumor immunity. Trends Immunol. 38, 668\u2013678 (2017).","journal-title":"Trends Immunol."},{"key":"38_CR13","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1818488116","volume":"116","author":"G Pizzolato","year":"2019","unstructured":"Pizzolato, G. et al. Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRV\u03b41 and TCRV\u03b42 \u03b3\u03b4 T lymphocytes. Proc.\u00a0Natl Acad. Sci. USA 116, 11906\u201311915 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"38_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","volume":"39","author":"KT Godder","year":"2007","unstructured":"Godder, K. T. et al. Long term disease-free survival in acute leukemia patients recovering with increased \u03b3\u03b4 T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 39, 751\u2013757 (2007).","journal-title":"Bone Marrow Transplant."},{"key":"38_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.bbmt.2014.09.027","volume":"21","author":"R Perko","year":"2015","unstructured":"Perko, R. et al. Gamma delta T cell reconstitution is associated with fewer infections and improved event-free survival after hematopoietic stem cell transplantation for pediatric leukemia. Biol. Blood Marrow Transplant. 21, 130\u2013136 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"38_CR16","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/leu.2012.374","volume":"27","author":"W Scheper","year":"2013","unstructured":"Scheper, W. et al. GammadeltaT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 27, 1328\u20131338 (2013).","journal-title":"Leukemia"},{"key":"38_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fimmu.2015.00003","volume":"6","author":"L Couzi","year":"2015","unstructured":"Couzi, L., Pitard, V., Moreau, J. F., Merville, P. & Dechanet-Merville, J. Direct and indirect effects of cytomegalovirus-induced \u03b3\u03b4 T cells after kidney transplantation. Front. Immunol. 6, 3 (2015).","journal-title":"Front. Immunol."},{"key":"38_CR18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/leu.2013.378","volume":"28","author":"W Scheper","year":"2014","unstructured":"Scheper, W., Grunder, C., Straetemans, T., Sebestyen, Z. & Kuball, J. Hunting for clinical translation with innate-like immune cells and their receptors. Leukemia 28, 1181\u20131190 (2014).","journal-title":"Leukemia"},{"key":"38_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3389\/fimmu.2018.00389","volume":"9","author":"NHR Litjens","year":"2018","unstructured":"Litjens, N. H. R., van der Wagen, L., Kuball, J. & Kwekkeboom, J. Potential beneficial effects of cytomegalovirus infection after transplantation. Front. Immunol. 9, 389 (2018).","journal-title":"Front. Immunol."},{"key":"38_CR20","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1182\/blood-2017-08-752162","volume":"131","author":"R Handgretinger","year":"2018","unstructured":"Handgretinger, R. & Schilbach, K. The potential role of \u03b3\u03b4 T cells after allogeneic HCT for leukemia. Blood\u00a0131, 1063\u20131072 (2018).","journal-title":"Blood"},{"key":"38_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1681\/ASN.2008101072","volume":"21","author":"L Couzi","year":"2009","unstructured":"Couzi, L. et al. Cytomegalovirus-induced \u03b3\u03b4 T cells associate with reduced cancer risk after kidney transplantation. J. Am. Soc. Nephrol. 21, 181\u2013188 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"38_CR22","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1084\/jem.20041851","volume":"201","author":"F Halary","year":"2005","unstructured":"Halary, F. et al. Shared reactivity of V\u03b42\u2013 \u03b3\u03b4 T cells against\u00a0cytomegalovirus-infected cells and tumor intestinal epithelial cells. J. Exp. Med. 201, 1567\u20131578 (2005).","journal-title":"J. Exp. Med."},{"key":"38_CR23","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3389\/fimmu.2014.00636","volume":"5","author":"DC Deniger","year":"2014","unstructured":"Deniger, D. C., Moyes, J. S. & Cooper, L. J. Clinical applications of \u03b3 \u03b4 T cells with multivalent immunity. Front. Immunol. 5, 636 (2014). This is a comprehensive review describing multiple\u00a0failures in clinical trials that have dealt with \u03b3\u03b4T cells in the past.","journal-title":"Front. Immunol."},{"key":"38_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0014-5793(03)00483-6","volume":"544","author":"M Eberl","year":"2003","unstructured":"Eberl, M. et al. Microbial isoprenoid biosynthesis and human \u03b3\u03b4T cell activation. FEBS Lett. 544, 4\u201310 (2003).","journal-title":"FEBS Lett."},{"key":"38_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.semcdb.2018.02.007","volume":"84","author":"S Gu","year":"2018","unstructured":"Gu, S., Borowska, M. T., Boughter, C. T. & Adams, E. J. Butyrophilin3A proteins and V\u03b39V\u03b42 T cell activation. Semin. Cell Dev. Biol. 84, 65\u201374 (2018).","journal-title":"Semin. Cell Dev. Biol."},{"key":"38_CR26","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1007\/s00018-017-2583-0","volume":"74","author":"M Moulin","year":"2017","unstructured":"Moulin, M. et al. V\u03b39V\u03b42 T cell activation by strongly agonistic nucleotidic phosphoantigens. Cell Mol. Life Sci. 74, 4353\u20134367 (2017).","journal-title":"Cell Mol. Life Sci."},{"key":"38_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","volume":"102","author":"M Wilhelm","year":"2003","unstructured":"Wilhelm, M. et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200\u2013206 (2003).","journal-title":"Blood"},{"key":"38_CR28","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","volume":"67","author":"F Dieli","year":"2007","unstructured":"Dieli, F. et al. Targeting human \u03b3\u03b4 T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450\u20137457 (2007).","journal-title":"Cancer Res."},{"key":"38_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/QAD.0b013e3283244619","volume":"23","author":"F Poccia","year":"2009","unstructured":"Poccia, F. et al. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating V\u03b39V\u03b42 T cells. AIDS 23, 555\u2013565 (2009).","journal-title":"AIDS"},{"key":"38_CR30","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s00262-010-0879-0","volume":"59","author":"J Bennouna","year":"2010","unstructured":"Bennouna, J. et al. Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a V\u03b39V\u03b42 T lymphocyte agonist in patients with solid tumors. Cancer Immunol. Immunother. 59, 1521\u20131530 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"38_CR31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","volume":"161","author":"S Meraviglia","year":"2010","unstructured":"Meraviglia, S. et al. In vivo manipulation of V\u03b39V\u03b42 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161, 290\u2013297 (2010).","journal-title":"Clin. Exp. Immunol."},{"key":"38_CR32","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","volume":"60","author":"JM Lang","year":"2011","unstructured":"Lang, J. M. et al. Pilot trial of interleukin-2 and zoledronic acid to augment \u03b3\u03b4 T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol. Immunother. 60, 1447\u20131460 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"38_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CJI.0b013e318245bb1e","volume":"35","author":"V Kunzmann","year":"2012","unstructured":"Kunzmann, V. et al. Tumor-promoting versus tumor-antagonizing roles of \u03b3\u03b4 T cells in cancer immunotherapy: results from a prospective phase I\/II trial. J. Immunother. 35, 205\u2013213 (2012).","journal-title":"J. Immunother."},{"key":"38_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004909","volume":"95","author":"JG Pressey","year":"2016","unstructured":"Pressey, J. G. et al. In vivo expansion and activation of \u03b3\u03b4 T cells as immunotherapy for refractory neuroblastoma: a phase 1 study. Medicine (Baltimore) 95, e4909 (2016).","journal-title":"Medicine (Baltimore)"},{"key":"38_CR35","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1016\/j.bmcl.2012.07.092","volume":"22","author":"D Bregeon","year":"2012","unstructured":"Bregeon, D. et al. Synthesis of phosphoantigens: scalable accesses to enantiomers of BrHPP and studies on N-HDMAPP synthesis. Bioorg. Med. Chem. Lett. 22, 5807\u20135810 (2012).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"38_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00262-006-0199-6","volume":"56","author":"H Kobayashi","year":"2007","unstructured":"Kobayashi, H. et al. Safety profile and anti-tumor effects of adoptive immunotherapy using \u03b3-\u03b4 T cells against advanced renal cell carcinoma: a pilot study.\u00a0Cancer Immunol. Immunother. 56, 469\u2013476 (2007).","journal-title":"Cancer Immunol. Immunother."},{"key":"38_CR37","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1007\/s00262-008-0491-8","volume":"57","author":"J Bennouna","year":"2008","unstructured":"Bennouna, J. et al. Phase-I study of Innacell \u03b3\u03b4, an autologous cell-therapy product highly enriched in \u03b39\u03b42 T lymphocytes, in combination with IL-2, in\u00a0patients with metastatic renal cell carcinoma. Cancer\u00a0Immunol. Immunother. 57, 1599\u20131609 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"38_CR38","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.exphem.2009.04.008","volume":"37","author":"Y Abe","year":"2009","unstructured":"Abe, Y. et al. Clinical and immunological evaluation of zoledronate-activated V\u03b39\u03b3\u03b4 T-cell-based immunotherapy for patients with multiple myeloma. Exp. Hematol. 37, 956\u2013968 (2009).","journal-title":"Exp. Hematol."},{"key":"38_CR39","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.ejcts.2009.11.051","volume":"37","author":"J Nakajima","year":"2010","unstructured":"Nakajima, J. et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous \u03b3\u03b4 T cells. Eur. J. Cardiothorac. Surg. 37, 1191\u20131197 (2010).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"38_CR40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00262-011-1021-7","volume":"60","author":"H Kobayashi","year":"2011","unstructured":"Kobayashi, H., Tanaka, Y., Yagi, J., Minato, N. & Tanabe, K. Phase I\/II study of adoptive transfer of \u03b3\u03b4 T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer\u00a0Immunol. Immunother. 60, 1075\u20131084 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"38_CR41","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/bjc.2011.293","volume":"105","author":"AJ Nicol","year":"2011","unstructured":"Nicol, A. J. et al. Clinical evaluation of autologous \u03b3 \u03b4 T cell-based immunotherapy for metastatic solid tumours. Br. J. Cancer 105, 778\u2013786 (2011).","journal-title":"Br. J. Cancer"},{"key":"38_CR42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/14653249.2010.515581","volume":"13","author":"A Noguchi","year":"2011","unstructured":"Noguchi, A. et al. Zoledronate-activated V\u03b39\u03b3\u03b4 T cell-based immunotherapy is feasible and restores the impairment of \u03b3\u03b4 T cells in patients with solid tumors. Cytotherapy 13, 92\u201397 (2011).","journal-title":"Cytotherapy"},{"key":"38_CR43","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1097\/CJI.0b013e318207ecfb","volume":"34","author":"M Sakamoto","year":"2011","unstructured":"Sakamoto, M. et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded \u03b3\u03b4T cells: a phase I clinical study. J. Immunother. 34, 202\u2013211 (2011).","journal-title":"J. Immunother."},{"key":"38_CR44","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/ijc.28372","volume":"134","author":"J Cui","year":"2014","unstructured":"Cui, J. et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int. J. Cancer 134, 342\u2013351 (2014).","journal-title":"Int. J. Cancer"},{"key":"38_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jcyt.2012.12.004","volume":"15","author":"T Izumi","year":"2013","unstructured":"Izumi, T. et al. Ex vivo characterization of \u03b3\u03b4 T-cell repertoire in patients after adoptive transfer of V\u03b39V\u03b42 T cells expressing the interleukin-2 receptor beta-chain and the common \u03b3-chain. Cytotherapy 15, 481\u2013491 (2013).","journal-title":"Cytotherapy"},{"key":"38_CR46","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/cam4.196","volume":"3","author":"I Wada","year":"2014","unstructured":"Wada, I. et al. Intraperitoneal injection of in vitro expanded V\u03b39V\u03b42 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med. 3, 362\u2013375 (2014).","journal-title":"Cancer Med."},{"key":"38_CR47","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jcyt.2017.01.002","volume":"19","author":"T Aoki","year":"2017","unstructured":"Aoki, T. et al. Adjuvant combination therapy with gemcitabine and autologous \u03b3\u03b4 T-cell transfer in patients with curatively resected pancreatic cancer. Cytotherapy 19, 473\u2013485 (2017).","journal-title":"Cytotherapy"},{"key":"38_CR48","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1089\/scd.1.1996.5.503","volume":"5","author":"LS Lamb Jr.","year":"1996","unstructured":"Lamb, L. S. Jr et al. Increased frequency of TCR \u03b3\u03b4+ T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J. Hematother. 5, 503\u2013509 (1996). This article is the first clinical description of the potential benefit of \u03b3\u03b4T cells after allogeneic stem cell transplantation.","journal-title":"J. Hematother."},{"key":"38_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-45","volume":"12","author":"M Wilhelm","year":"2014","unstructured":"Wilhelm, M. et al. Successful adoptive transfer and in vivo expansion of haploidentical \u03b3\u03b4 T cells. J. Transl Med. 12, 45 (2014).","journal-title":"J Transl Med"},{"key":"38_CR50","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1084\/jem.179.1.323","volume":"179","author":"EP Rock","year":"1994","unstructured":"Rock, E. P., Sibbald, P. R., Davis, M. M. & Chien, Y. H. CDR3 length in antigen-specific immune receptors. J. Exp. Med. 179, 323\u2013328 (1994).","journal-title":"J. Exp. Med."},{"key":"38_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0092-8674(94)90170-8","volume":"76","author":"H Schild","year":"1994","unstructured":"Schild, H. et al. The nature of major histocompatibility complex recognition by \u03b3 \u03b4 T cells. Cell 76, 29\u201337 (1994).","journal-title":"Cell"},{"key":"38_CR52","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/331627a0","volume":"331","author":"JF Elliott","year":"1988","unstructured":"Elliott, J. F., Rock, E. P., Patten, P. A., Davis, M. M. & Chien, Y. H. The adult T-cell receptor \u03b4-chain is diverse and distinct from that of fetal thymocytes. Nature 331, 627\u2013631 (1988).","journal-title":"Nature"},{"key":"38_CR53","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1084\/jem.170.5.1521","volume":"170","author":"G Casorati","year":"1989","unstructured":"Casorati, G., De Libero, G., Lanzavecchia, A. & Migone, N. Molecular analysis of human \u03b3\/\u03b4+ clones from thymus and peripheral blood. J. Exp. Med. 170, 1521\u20131535 (1989).","journal-title":"J. Exp. Med."},{"key":"38_CR54","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/ni.3686","volume":"18","author":"S Ravens","year":"2017","unstructured":"Ravens, S. et al. Human \u03b3\u03b4 T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. Nat. Immunol. 18, 393\u2013401 (2017). This is a comprehensive analysis of the \u03b3\u03b4T cell repertoire after allogeneic stem cell transplantation.","journal-title":"Nat. Immunol."},{"key":"38_CR55","doi-asserted-by":"publisher","first-page":"90ra61","DOI":"10.1126\/scitranslmed.3002536","volume":"3","author":"AM Sherwood","year":"2011","unstructured":"Sherwood, A. M. et al. Deep sequencing of the human TCR\u03b3 and TCR\u03b2 repertoires suggests that TCR\u03b2 rearranges after \u03b1\u03b2 and \u03b3\u03b4 T cell commitment. Sci. Transl Med. 3, 90ra61 (2011).","journal-title":"Sci. Transl Med."},{"key":"38_CR56","doi-asserted-by":"publisher","first-page":"E556","DOI":"10.1073\/pnas.1412058112","volume":"112","author":"T Dimova","year":"2015","unstructured":"Dimova, T. et al. Effector V\u03b39V\u03b42 T cells dominate the human fetal \u03b3\u03b4 T-cell repertoire. Proc. Natl Acad. Sci. USA 112, E556\u2013E565 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"38_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04076-0","volume":"9","author":"MS Davey","year":"2018","unstructured":"Davey, M. S. et al. The human V\u03b42+ T-cell compartment comprises distinct innate-like V\u03b39+ and adaptive V\u03b39\u2212 subsets. Nat. Commun. 9, 1760 (2018).","journal-title":"Nat. Commun."},{"key":"38_CR58","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1126\/science.1978758","volume":"250","author":"P Fisch","year":"1990","unstructured":"Fisch, P. et al. Recognition by human V\u03b39\/V\u03b42 T cells of a GroEL homolog on Daudi Burkitt\u2019s lymphoma cells. Science 250, 1269\u20131273 (1990).","journal-title":"Science"},{"key":"38_CR59","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1182\/blood-2012-05-432427","volume":"120","author":"C Grunder","year":"2012","unstructured":"Grunder, C. et al. Gamma9 and \u03b42CDR3 domains regulate functional avidity of T cells harboring \u03b39\u03b42TCRs. Blood 120, 5153\u20135162 (2012). This article describes the impacts of different CDR3 domains on the functional avidity of TEGs.","journal-title":"Blood"},{"key":"38_CR60","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/eji.201646818","volume":"47","author":"L Starick","year":"2017","unstructured":"Starick, L. et al. Butyrophilin 3 A (BTN3A, CD277)-specific antibody 20.1 differentially activates V\u03b39V\u03b42 TCR clonotypes and interferes with phosphoantigen activation. Eur. J. Immunol. 47, 982\u2013992 (2017).","journal-title":"Eur. J. Immunol."},{"key":"38_CR61","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.4049\/jimmunol.1000231","volume":"184","author":"H Wang","year":"2010","unstructured":"Wang, H., Fang, Z. & Morita, C. T. V\u03b32V\u03b42 T. cell receptor recognition of prenyl pyrophosphates is dependent on all CDRs. J. Immunol. 184, 6209\u20136222 (2010).","journal-title":"J. Immunol."},{"key":"38_CR62","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3389\/fimmu.2018.01501","volume":"9","author":"CR Willcox","year":"2018","unstructured":"Willcox, C. R., Davey, M. S. & Willcox, B. E. Development and Selection of the Human V\u03b39V\u03b42(+) T-Cell Repertoire. Front. Immunol. 9, 1501 (2018).","journal-title":"Front. Immunol."},{"key":"38_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14760","volume":"8","author":"MS Davey","year":"2017","unstructured":"Davey, M. S. et al. Clonal selection in the human V\u03b41\u00a0T cell repertoire indicates \u03b3\u03b4 TCR-dependent adaptive immune surveillance. Nat. Commun. 8, 14760 (2017).","journal-title":"Nat. Commun."},{"key":"38_CR64","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood-2008-01-136713","volume":"112","author":"V Pitard","year":"2008","unstructured":"Pitard, V. et al. Long-term expansion of effector\/memory V\u03b42-\u03b3\u03b4 T cells is a specific blood signature of\u00a0CMV infection. Blood 112, 1317\u20131324 (2008). This article analyses the correlation between cytomegalovirus infection and \u03b3\u03b4T cell expansion.","journal-title":"Blood"},{"key":"38_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/314568","volume":"179","author":"J Dechanet","year":"1999","unstructured":"Dechanet, J. et al. Major expansion of \u03b3\u03b4 T lymphocytes following cytomegalovirus infection in kidney allograft recipients. J. Infect. Dis. 179, 1\u20138 (1999).","journal-title":"J. Infect. Dis."},{"key":"38_CR66","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1172\/JCI5409","volume":"103","author":"J Dechanet","year":"1999","unstructured":"Dechanet, J. et al. Implication of \u03b3\u03b4 T cells in the human immune response to cytomegalovirus. J. Clin. Invest 103, 1437\u20131449 (1999).","journal-title":"J. Clin. Invest"},{"key":"38_CR67","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3389\/fimmu.2018.00448","volume":"9","author":"MJ Kallemeijn","year":"2018","unstructured":"Kallemeijn, M. J. et al. Next-generation sequencing analysis of the human TCR\u03b3\u03b4+ T-cell repertoire reveals shifts in v\u03b3- and v\u03b4-usage in memory populations upon aging. Front. Immunol. 9, 448 (2018).","journal-title":"Front. Immunol."},{"key":"38_CR68","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3389\/fimmu.2014.00601","volume":"5","author":"W Scheper","year":"2014","unstructured":"Scheper, W., Sebestyen, Z. & Kuball, J. Cancer immunotherapy using \u03b3\u03b4t cells: dealing with diversity. Front. Immunol. 5, 601 (2014).","journal-title":"Front. Immunol."},{"key":"38_CR69","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nri797","volume":"2","author":"SR Carding","year":"2002","unstructured":"Carding, S. R. & Egan, P. J. \u03b3\u03b4 T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2, 336\u2013345 (2002).","journal-title":"Nat.Rev.Immunol."},{"key":"38_CR70","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3389\/fimmu.2018.00985","volume":"9","author":"NE McCarthy","year":"2018","unstructured":"McCarthy, N. E. & Eberl, M. Human \u03b3\u03b4 T-cell control\u00a0of\u00a0mucosal immunity and inflammation. Front.\u00a0Immunol. 9, 985 (2018).","journal-title":"Front. Immunol."},{"key":"38_CR71","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41590-018-0253-5","volume":"19","author":"D Melandri","year":"2018","unstructured":"Melandri, D. et al. The \u03b3\u03b4TCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness. Nat. Immunol. 19, 1352\u20131365 (2018).","journal-title":"Nat. Immunol."},{"key":"38_CR72","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cell.2016.08.030","volume":"167","author":"R Di Marco Barros","year":"2016","unstructured":"Di Marco Barros, R. et al. Epithelia use butyrophilin-like molecules to shape organ-specific \u03b3\u03b4 T cell compartments. Cell 167, 203\u2013218 (2016).","journal-title":"Cell"},{"key":"38_CR73","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1084\/jem.20181439","volume":"215","author":"I Sandrock","year":"2018","unstructured":"Sandrock, I. et al. Genetic models reveal origin, persistence and non-redundant functions of IL-17-producing \u03b3\u03b4 T cells. J. Exp. Med. 215, 3006\u20133018 (2018).","journal-title":"J. Exp. Med."},{"key":"38_CR74","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/ni.2394","volume":"13","author":"CR Willcox","year":"2012","unstructured":"Willcox, C. R. et al. Cytomegalovirus and tumor stress surveillance by binding of a human \u03b3\u03b4 T cell antigen receptor to endothelial protein C receptor. Nat. Immunol. 13, 872\u2013879 (2012).","journal-title":"Nat. Immunol."},{"key":"38_CR75","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.celrep.2016.04.081","volume":"15","author":"Z Sebestyen","year":"2016","unstructured":"Sebestyen, Z. et al. Rhob mediates phosphoantigen recognition by V\u03b39V\u03b42 T cell receptor. Cell Rep. 15, 1973\u20131985 (2016). This is the first article to describe the key role of the small GTPase RhoB in regulation of CD277J.","journal-title":"Cell Rep."},{"key":"38_CR76","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27\u201347 (2016).","journal-title":"Cell Metab."},{"key":"38_CR77","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189\u20132199 (2014).","journal-title":"N. Engl. J. Med."},{"key":"38_CR78","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1084\/jem.20021500","volume":"197","author":"HJ Gober","year":"2003","unstructured":"Gober, H. J. et al. Human T cell receptor \u03b3\u03b4 cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197, 163\u2013168 (2003).","journal-title":"J. Exp. Med."},{"key":"38_CR79","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/375155a0","volume":"375","author":"Y Tanaka","year":"1995","unstructured":"Tanaka, Y. et al. Natural and synthetic non-peptide antigens recognized by human \u03b3 \u03b4 T cells. Nature 375, 155\u2013158 (1995).","journal-title":"Nature"},{"key":"38_CR80","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.4049\/jimmunol.0901085","volume":"183","author":"P Vantourout","year":"2009","unstructured":"Vantourout, P. et al. Specific requirements for V\u03b39V\u03b42 T cell stimulation by a natural adenylated phosphoantigen. J. Immunol. 183, 3848\u20133857 (2009).","journal-title":"J. Immunol."},{"key":"38_CR81","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.bbrc.2015.05.118","volume":"463","author":"E Ashihara","year":"2015","unstructured":"Ashihara, E. et al. Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of \u03b3\u03b4T cells. Biochem. Biophys. Res. Commun. 463, 650\u2013655 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"38_CR82","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2012-05-430470","volume":"120","author":"C Harly","year":"2012","unstructured":"Harly, C. et al. Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset. Blood 120, 2269\u20132279 (2012). This article emphasizes the key role of CD277 in V\u03b39V\u03b42 T cell recognition.","journal-title":"Blood"},{"key":"38_CR83","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3389\/fimmu.2018.00828","volume":"9","author":"L Boutin","year":"2018","unstructured":"Boutin, L. & Scotet, E. Towards deciphering the hidden mechanisms that contribute to the antigenic activation process of human V\u03b39V\u03b42 T cells. Front. Immunol. 9, 828 (2018).","journal-title":"Front. Immunol."},{"key":"38_CR84","doi-asserted-by":"publisher","first-page":"E7311","DOI":"10.1073\/pnas.1707547114","volume":"114","author":"S Gu","year":"2017","unstructured":"Gu, S. et al. Phosphoantigen-induced conformational change of butyrophilin 3A1 (BTN3A1) and its implication on V\u03b39V\u03b42 T cell activation. Proc. Natl Acad. Sci. USA 114, E7311\u2013E7320 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"38_CR85","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.4049\/jimmunol.1601910","volume":"198","author":"CM Peigne","year":"2017","unstructured":"Peigne, C. M. et al. The juxtamembrane domain of butyrophilin btn3a1 controls phosphoantigen-mediated activation of human V\u03b39V\u03b42 T cells. J. Immunol. 198, 4228\u20134234 (2017).","journal-title":"J. Immunol."},{"key":"38_CR86","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1096\/fj.201601370RR","volume":"31","author":"K Nguyen","year":"2017","unstructured":"Nguyen, K. et al. The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region. FASEB J. 31, 4697\u20134706 (2017).","journal-title":"FASEB J."},{"key":"38_CR87","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.4049\/jimmunol.1401064","volume":"194","author":"DA Rhodes","year":"2015","unstructured":"Rhodes, D. A. et al. Activation of human \u03b3\u03b4 T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin. J. Immunol. 194, 2390\u20132398 (2015).","journal-title":"J. Immunol."},{"key":"38_CR88","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1073\/pnas.1701237115","volume":"115","author":"P Vantourout","year":"2018","unstructured":"Vantourout, P. et al. Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing \u03b3\u03b4 T cell biology. Proc. Natl Acad. Sci. USA 115, 1039\u20131044 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"38_CR89","doi-asserted-by":"publisher","first-page":"16812","DOI":"10.1074\/jbc.M111.327650","volume":"287","author":"Y Dai","year":"2012","unstructured":"Dai, Y., Chen, H., Mo, C., Cui, L. & He, W. Ectopically expressed human tumor biomarker MutS homologue 2 is a novel endogenous ligand that is recognized by human \u03b3\u03b4 T cells to induce innate anti-tumor\/virus\u00a0immunity. J. Biol. Chem. 287, 16812\u201316819 (2012).","journal-title":"J. Biol. Chem."},{"key":"38_CR90","doi-asserted-by":"publisher","first-page":"19242","DOI":"10.1074\/jbc.M112.349936","volume":"287","author":"C Mo","year":"2012","unstructured":"Mo, C., Dai, Y., Kang, N., Cui, L. & He, W. Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways. J. Biol. Chem. 287, 19242\u201319254 (2012).","journal-title":"J. Biol. Chem."},{"key":"38_CR91","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.immuni.2004.11.012","volume":"22","author":"E Scotet","year":"2005","unstructured":"Scotet, E. et al. Tumor recognition following V\u03b39V\u03b42 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22, 71\u201380 (2005).","journal-title":"Immunity"},{"key":"38_CR92","doi-asserted-by":"publisher","first-page":"19985","DOI":"10.1074\/jbc.M115.700070","volume":"291","author":"H Chen","year":"2016","unstructured":"Chen, H. et al. Chaperonin-containing T-complex protein 1 subunit zeta serves as an autoantigen recognized by human V\u03b42 \u03b3\u03b4 T cells in autoimmune diseases. J. Biol. Chem. 291, 19985\u201319993 (2016).","journal-title":"J. Biol. Chem."},{"key":"38_CR93","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/ng.108","volume":"40","author":"LM Boyden","year":"2008","unstructured":"Boyden, L. M. et al. Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal \u03b3\u03b4 T cells. Nat. Genet. 40, 656\u2013662 (2008).","journal-title":"Nat. Genet."},{"key":"38_CR94","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.semcdb.2017.10.009","volume":"84","author":"D Vermijlen","year":"2018","unstructured":"Vermijlen, D., Gatti, D., Kouzeli, A., Rus, T. & Eberl, M. Gammadelta T cell responses: how many ligands will it take till we know? Semin. Cell Dev. Biol. 84, 75\u201386 (2018).","journal-title":"Semin. Cell Dev. Biol."},{"key":"38_CR95","doi-asserted-by":"publisher","first-page":"929","DOI":"10.3389\/fimmu.2018.00929","volume":"9","author":"AE Simoes","year":"2018","unstructured":"Simoes, A. E., Di Lorenzo, B. & Silva-Santos, B. Molecular determinants of target cell recognition by human \u03b3\u03b4 T cells. Front. Immunol. 9, 929 (2018).","journal-title":"Front. Immunol."},{"key":"38_CR96","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cellimm.2015.04.008","volume":"296","author":"EJ Adams","year":"2015","unstructured":"Adams, E. J., Gu, S. & Luoma, A. M. Human \u03b3 \u03b4 T cells: evolution and ligand recognition. Cell Immunol. 296, 31\u201340 (2015).","journal-title":"Cell Immunol."},{"key":"38_CR97","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.it.2014.09.003","volume":"35","author":"AM Luoma","year":"2014","unstructured":"Luoma, A. M., Castro, C. D. & Adams, E. J. \u03b3\u03b4 T cell surveillance via CD1 molecules. Trends Immunol. 35, 613\u2013621 (2014).","journal-title":"Trends Immunol."},{"key":"38_CR98","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/ni.2713","volume":"14","author":"AP Uldrich","year":"2013","unstructured":"Uldrich, A. P. et al. CD1d-lipid antigen recognition by\u00a0the \u03b3\u03b4 TCR. Nat. Immunol. 14, 1137\u20131145 (2013).","journal-title":"Nat. Immunol."},{"key":"38_CR99","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.immuni.2013.11.001","volume":"39","author":"AM Luoma","year":"2013","unstructured":"Luoma, A. M. et al. Crystal structure of V\u03b41 T cell receptor in complex with CD1d-sulfatide shows MHC-like recognition of a self-lipid by human \u03b3\u03b4\u00a0T cells. Immunity 39, 1032\u20131042 (2013).","journal-title":"Immunity"},{"key":"38_CR100","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4049\/jimmunol.1300121","volume":"191","author":"BA Mangan","year":"2013","unstructured":"Mangan, B. A. et al. Cutting edge: CD1d restriction and Th1\/Th2\/Th17 cytokine secretion by human V\u03b43\u00a0T cells. J. Immunol. 191, 30\u201334 (2013).","journal-title":"J. Immunol."},{"key":"38_CR101","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1084\/jem.20140410","volume":"211","author":"M Lepore","year":"2014","unstructured":"Lepore, M. et al. A novel self-lipid antigen targets human T cells against CD1c(+) leukemias. J. Exp. Med. 211, 1363\u20131377 (2014).","journal-title":"J. Exp. Med."},{"key":"38_CR102","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.4049\/jimmunol.1502202","volume":"196","author":"S Roy","year":"2016","unstructured":"Roy, S. et al. Molecular analysis of lipid-reactive v\u03b41 \u03b3\u03b4 T cells identified by CD1C tetramers. J. Immunol. 196, 1933\u20131942 (2016).","journal-title":"J. Immunol."},{"key":"38_CR103","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.immuni.2013.11.016","volume":"39","author":"A Hayday","year":"2013","unstructured":"Hayday, A. & Vantourout, P. A long-playing CD about the \u03b3\u03b4 TCR repertoire. Immunity 39, 994\u2013996 (2013).","journal-title":"Immunity"},{"key":"38_CR104","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1073\/pnas.96.12.6879","volume":"96","author":"V Groh","year":"1999","unstructured":"Groh, V. et al. Broad tumor-associated expression and recognition by tumor-derived \u03b3\u03b4 T cells of MICA and MICB. Proc. Natl Acad. Sci. USA 96, 6879\u20136884 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"38_CR105","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/ni.2689","volume":"14","author":"CR Willcox","year":"2013","unstructured":"Willcox, C. R., Mohammed, F. & Willcox, B. E. Resolving the mystery of pyrophosphate antigen presentation. Nat. Immunol. 14, 886\u2013887 (2013).","journal-title":"Nat. Immunol."},{"key":"38_CR106","first-page":"6871","volume":"52","author":"SA Reeves","year":"1992","unstructured":"Reeves, S. A., Chavez-Kappel, C., Davis, R., Rosenblum, M. & Israel, M. A. Developmental regulation of annexin II (Lipocortin 2) in human brain and expression in high grade glioma. Cancer Res. 52, 6871\u20136876 (1992).","journal-title":"Cancer Res."},{"key":"38_CR107","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1073\/pnas.1621052114","volume":"114","author":"R Marlin","year":"2017","unstructured":"Marlin, R. et al. Sensing of cell stress by human \u03b3\u03b4 TCR-dependent recognition of annexin A2. Proc. Natl Acad. Sci. USA 114, 3163\u20133168 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"38_CR108","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1158\/1078-0432.CCR-16-0597","volume":"22","author":"AR Almeida","year":"2016","unstructured":"Almeida, A. R. et al. Delta one t cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion\/differentiation and preclinical proof of concept. Clin. Cancer Res. 22, 5795\u20135804 (2016). This article presents a comprehensive description of the DOT cell concept.","journal-title":"Clin. Cancer Res."},{"key":"38_CR109","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1002\/eji.1830271111","volume":"27","author":"F Halary","year":"1997","unstructured":"Halary, F. et al. Control of self-reactive cytotoxic T lymphocytes expressing \u03b3 \u03b4 T cell receptors by natural killer inhibitory receptors. Eur. J. Immunol. 27, 2812\u20132821 (1997).","journal-title":"Eur. J. Immunol."},{"key":"38_CR110","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1086\/644509","volume":"200","author":"L Couzi","year":"2009","unstructured":"Couzi, L. et al. Common features of \u03b3\u03b4 T cells and CD8(+) alphabeta T cells responding to human cytomegalovirus infection in kidney transplant recipients. J. Infect. Dis. 200, 1415\u20131424 (2009).","journal-title":"J. Infect. Dis."},{"key":"38_CR111","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.4049\/jimmunol.177.9.6129","volume":"177","author":"V Trichet","year":"2006","unstructured":"Trichet, V. et al. Complex interplay of activating and inhibitory signals received by V\u03b39V\u03b42 T cells revealed by target cell beta2-microglobulin knockdown. J.\u00a0Immunol. 177, 6129\u20136136 (2006).","journal-title":"J. Immunol."},{"key":"38_CR112","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2010.08.031","volume":"142","author":"MT Orr","year":"2010","unstructured":"Orr, M. T. & Lanier, L. L. Natural killer cell education and tolerance. Cell 142, 847\u2013856 (2010).","journal-title":"Cell"},{"key":"38_CR113","unstructured":"Benveniste, P. M. et al. Generation and molecular recognition of melanoma-associated antigen-specific human \u03b3\u03b4 T cells. Sci. Immunol. 3, eaav4036 (2018)."},{"key":"38_CR114","unstructured":"Kierkels, G. et al. Identification of a tumor-specific allo-HLA-restricted \u03b3\u03b4TCR. Blood Adv. (in the press)."},{"key":"38_CR115","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00262-015-1710-8","volume":"64","author":"MA de Witte","year":"2015","unstructured":"de Witte, M. A., Kierkels, G. J., Straetemans, T., Britten, C. M. & Kuball, J. Orchestrating an immune response against cancer with engineered immune cells expressing alphabetaTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge. Cancer Immunol. Immunother. 64, 893\u2013902 (2015).","journal-title":"Cancer Immunol. Immunother."},{"key":"38_CR116","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/eji.200939222","volume":"39","author":"DL Gibbons","year":"2009","unstructured":"Gibbons, D. L. et al. Neonates harbour highly active \u03b3\u03b4 T cells with selective impairments in preterm infants. Eur. J. Immunol. 39, 1794\u20131806 (2009).","journal-title":"Eur. J. Immunol."},{"key":"38_CR117","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.4049\/jimmunol.1303119","volume":"192","author":"JC Ribot","year":"2014","unstructured":"Ribot, J. C., Ribeiro, S. T., Correia, D. V., Sousa, A. E. & Silva-Santos, B. Human \u03b3\u03b4 thymocytes are functionally immature and differentiate into cytotoxic type 1 effector T cells upon IL-2\/IL-15 signaling. J.\u00a0Immunol. 192, 2237\u20132243 (2014).","journal-title":"J. Immunol."},{"key":"38_CR118","doi-asserted-by":"publisher","first-page":"14378","DOI":"10.1073\/pnas.1611098113","volume":"113","author":"PL Ryan","year":"2016","unstructured":"Ryan, P. L. et al. Heterogeneous yet stable V\u03b42+ T-cell profiles define distinct cytotoxic effector potentials in healthy human individuals. Proc. Natl Acad. Sci. USA 113, 14378\u201314383 (2016). This article analyses the heterogeneity in profiles of V\u03b42 + \u03b3\u03b4T cells.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"38_CR119","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.cell.2016.07.046","volume":"166","author":"D Daley","year":"2016","unstructured":"Daley, D. et al. Gammadelta T cells support pancreatic oncogenesis by restraining alphabeta T cell activation. Cell 166, 1485\u20131499 e1415 (2016).","journal-title":"Cell"},{"key":"38_CR120","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3389\/fimmu.2014.00607","volume":"5","author":"E Lo Presti","year":"2014","unstructured":"Lo Presti, E., Dieli, F. & Meraviglia, S. Tumor-infiltrating \u03b3\u03b4 T lymphocytes: pathogenic role, clinical significance, and differential programing in the tumor microenvironment. Front. Immunol. 5, 607 (2014).","journal-title":"Front. Immunol."},{"key":"38_CR121","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.trecan.2017.06.003","volume":"3","author":"C Fleming","year":"2017","unstructured":"Fleming, C., Morrissey, S., Cai, Y. & Yan, J. Gammadelta T cells: unexpected regulators of cancer development and progression. Trends Cancer 3, 561\u2013570 (2017).","journal-title":"Trends Cancer"},{"key":"38_CR122","doi-asserted-by":"publisher","first-page":"E3562","DOI":"10.1073\/pnas.1403424111","volume":"111","author":"M Rei","year":"2014","unstructured":"Rei, M. et al. Murine CD27\u2013 V\u03b36(+) \u03b3\u03b4 T cells producing IL-17A promote ovarian cancer growth via\u00a0mobilization of protumor small peritoneal macrophages. Proc. Natl Acad. Sci. USA 111, E3562\u2013E3570 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"38_CR123","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1002\/eji.200940157","volume":"40","author":"D Wakita","year":"2010","unstructured":"Wakita, D. et al. Tumor-infiltrating IL-17-producing \u03b3\u03b4 T cells support the progression of tumor by promoting angiogenesis. Eur. J. Immunol. 40, 1927\u20131937 (2010).","journal-title":"Eur. J. Immunol."},{"key":"38_CR124","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ccr.2014.03.014","volume":"25","author":"F McAllister","year":"2014","unstructured":"McAllister, F. et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25, 621\u2013637 (2014).","journal-title":"Cancer Cell"},{"key":"38_CR125","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt, S. B. et al. IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522, 345\u2013348 (2015).","journal-title":"Nature"},{"key":"38_CR126","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2011-01-331298","volume":"118","author":"N Caccamo","year":"2011","unstructured":"Caccamo, N. et al. Differentiation, phenotype, and function of interleukin-17-producing human V\u03b39V\u03b42 T cells. Blood 118, 129\u2013138 (2011).","journal-title":"Blood"},{"key":"38_CR127","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ijc.30134","volume":"139","author":"RS Patil","year":"2016","unstructured":"Patil, R. S. et al. IL17 producing \u03b3\u03b4T cells induce angiogenesis and are associated with poor survival in\u00a0gallbladder cancer patients. Int. J. Cancer 139, 869\u2013881 (2016).","journal-title":"Int. J. Cancer"},{"key":"38_CR128","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.immuni.2007.05.020","volume":"27","author":"G Peng","year":"2007","unstructured":"Peng, G. et al. Tumor-infiltrating \u03b3\u03b4 T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity 27, 334\u2013348 (2007).","journal-title":"Immunity"},{"key":"38_CR129","doi-asserted-by":"publisher","first-page":"5029","DOI":"10.4049\/jimmunol.1201892","volume":"189","author":"C Ma","year":"2012","unstructured":"Ma, C. et al. Tumor-infiltrating \u03b3\u03b4 T lymphocytes predict clinical outcome in human breast cancer. J. Immunol. 189, 5029\u20135036 (2012).","journal-title":"J. Immunol."},{"key":"38_CR130","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1158\/0008-5472.CAN-13-0348","volume":"73","author":"J Ye","year":"2013","unstructured":"Ye, J. et al. Specific recruitment of \u03b3\u03b4 regulatory T cells in human breast cancer. Cancer Res. 73, 6137\u20136148 (2013).","journal-title":"Cancer Res."},{"key":"38_CR131","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.4049\/jimmunol.1202369","volume":"190","author":"J Ye","year":"2013","unstructured":"Ye, J. et al. Tumor-derived \u03b3\u03b4 regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence. J. Immunol. 190, 2403\u20132414 (2013).","journal-title":"J. Immunol."},{"key":"38_CR132","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1375641","volume":"7","author":"RCG de Bruin","year":"2017","unstructured":"de Bruin, R. C. G. et al. A bispecific nanobody approach to leverage the potent and widely applicable\u00a0tumor cytolytic capacity of V\u03b39V\u03b42-T cells. Oncoimmunology 7, e1375641 (2017).","journal-title":"Oncoimmunology"},{"key":"38_CR133","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","volume":"20","author":"RE Kontermann","year":"2015","unstructured":"Kontermann, R. E. & Brinkmann, U. Bispecific antibodies. Drug Discov. Today 20, 838\u2013847 (2015).","journal-title":"Drug Discov. Today"},{"key":"38_CR134","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051805","volume":"8","author":"LS Lamb Jr.","year":"2013","unstructured":"Lamb, L. S. Jr et al. Engineered drug resistant \u03b3\u03b4 T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy. PLoS ONE 8, e51805 (2013).","journal-title":"PLoS ONE"},{"key":"38_CR135","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1182\/blood-2017-12-822569","volume":"132","author":"I de Weerdt","year":"2018","unstructured":"de Weerdt, I. et al. Improving CLL V\u03b39V\u03b42-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib. Blood 132, 2260\u20132272 (2018).","journal-title":"Blood"},{"key":"38_CR136","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2016.06.001","volume":"64","author":"K Wistuba-Hamprecht","year":"2016","unstructured":"Wistuba-Hamprecht, K. et al. Proportions of blood-borne V\u03b41+ and V\u03b42+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. Eur. J. Cancer 64, 116\u2013126 (2016).","journal-title":"Eur. J. Cancer"},{"key":"38_CR137","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1182\/blood-2011-02-339135","volume":"118","author":"DV Correia","year":"2011","unstructured":"Correia, D. V. et al. Differentiation of human peripheral blood V\u03b41+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 118, 992\u20131001 (2011).","journal-title":"Blood"},{"key":"38_CR138","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2326-6066.CIR-18-0647","volume":"7","author":"B Di Lorenzo","year":"2019","unstructured":"Di Lorenzo, B. et al. Broad cytotoxic targeting of acute myeloid leukemia by polyclonal \u03b41 T cells. Cancer Immunol. Res. 7, 552\u2013558 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"38_CR139","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2018","unstructured":"Capsomidis, A. et al. Chimeric antigen receptor-engineered human \u03b3\u03b4 T cells: enhanced cytotoxicity with retention of cross presentation. Mol. Ther. 26, 354\u2013365 (2018).","journal-title":"Mol. Ther."},{"key":"38_CR140","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3389\/fimmu.2018.01409","volume":"9","author":"J Fisher","year":"2018","unstructured":"Fisher, J. & Anderson, J. Engineering approaches in\u00a0human \u03b3\u03b4 T cells for cancer immunotherapy. Front.\u00a0Immunol. 9, 1409 (2018).","journal-title":"Front. Immunol."},{"key":"38_CR141","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li, Y., Hermanson, D. L., Moriarity, B. S. & Kaufman, D. S. Human IPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity. Cell Stem Cell 23, 181\u2013192 (2018).","journal-title":"Cell Stem Cell"},{"key":"38_CR142","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.bbmt.2018.02.023","volume":"24","author":"MA de Witte","year":"2018","unstructured":"de Witte, M. A. et al. Early reconstitution of nk and \u03b3\u03b4\u00a0T cells and its implication for the design of post-transplant immunotherapy. Biol. Blood Marrow Transplant. 24, 1152\u20131162 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"38_CR143","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann, J., Schussler-Lenz, M., Bondanza, A. & Buchholz, C. J. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol. Med. 9, 1183\u20131197 (2017).","journal-title":"EMBO Mol. Med."},{"key":"38_CR144","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23974","volume":"2","author":"W Scheper","year":"2013","unstructured":"Scheper, W., Grunder, C. & Kuball, J. Multifunctional \u03b3\u03b4 T cells and their receptors for targeted anticancer immunotherapy. Oncoimmunology 2, e23974 (2013).","journal-title":"Oncoimmunology"},{"key":"38_CR145","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2010-12-325993","volume":"118","author":"V Marcu-Malina","year":"2011","unstructured":"Marcu-Malina, V. et al. Redirecting alphabeta T cells against cancer cells by transfer of a broadly tumor-reactive \u03b3\u03b4T-cell receptor. Blood 118, 50\u201359 (2011).","journal-title":"Blood"},{"key":"38_CR146","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1158\/1078-0432.CCR-14-2860","volume":"21","author":"T Straetemans","year":"2015","unstructured":"Straetemans, T. et al. Untouched GMP-ready purified engineered immune cells to treat cancer. Clin. Cancer Res. 21, 3957\u20133968 (2015).","journal-title":"Clin. Cancer Res."},{"key":"38_CR147","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/nbt.3847","volume":"35","author":"A Bouchie","year":"2017","unstructured":"Bouchie, A., DeFrancesco, L., Sheridan, C. & Webb, S. Nature Biotechnology\u2019s academic spinouts of 2016. Nat. Biotechnol. 35, 322\u2013333 (2017).","journal-title":"Nat. Biotechnol."},{"key":"38_CR148","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1434465","volume":"7","author":"MVJ Braham","year":"2018","unstructured":"Braham, M. V. J. et al. Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model. Oncoimmunology 7, e1434465 (2018).","journal-title":"Oncoimmunology"},{"key":"38_CR149","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3389\/fimmu.2018.01062","volume":"9","author":"T Straetemans","year":"2018","unstructured":"Straetemans, T. et al. GMP-grade manufacturing of\u00a0T cells engineered to express a defined \u03b3\u03b4TCR. Front. Immunol. 9, 1062 (2018). This article presents a detailed description of the production of TEGs for clinical use.","journal-title":"Front. Immunol."},{"key":"38_CR150","unstructured":"Netherlands Trial Register. A phase I study to investigate the safety of TEG001 cell suspension for infusion in patients with relapsed\/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome (IPSS-R score\u2009>\u20094,5) or multiple myeloma. NTR https:\/\/www.trialregister.nl\/trial\/6357 (2017)."},{"key":"38_CR151","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"38_CR152","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar, K. S. et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol.\u00a0Cancer 17, 48 (2018).","journal-title":"Mol. Cancer"},{"key":"38_CR153","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/157340607779317544","volume":"3","author":"Y Tanaka","year":"2007","unstructured":"Tanaka, Y. et al. Synthesis of pyrophosphate-containing compounds that stimulate V\u03b32V\u03b42 T cells: application to cancer immunotherapy. Med. Chem. 3, 85\u201399 (2007).","journal-title":"Med. Chem."},{"key":"38_CR154","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"N van de Donk","year":"2018","unstructured":"van de Donk, N. & Usmani, S. Z. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front. Immunol. 9, 2134 (2018).","journal-title":"Front. Immunol."},{"key":"38_CR155","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1172\/JCI80840","volume":"125","author":"NE McCarthy","year":"2015","unstructured":"McCarthy, N. E. et al. Azathioprine therapy selectively ablates human V\u03b42(+) T cells in Crohn\u2019s disease. J Clin. Invest. 125, 3215\u20133225 (2015).","journal-title":"J Clin. Invest."},{"key":"38_CR156","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40425-019-0558-4","volume":"7","author":"I Johanna","year":"2019","unstructured":"Johanna, I. et al. Evaluating in vivo efficacy \u2014 toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells. J. Immunother. Cancer 7, 69 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"38_CR157","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"38_CR158","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/nature19768","volume":"538","author":"F Blokzijl","year":"2016","unstructured":"Blokzijl, F. et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature 538, 260\u2013264 (2016).","journal-title":"Nature"},{"key":"38_CR159","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.coi.2016.06.005","volume":"42","author":"ZW Chen","year":"2016","unstructured":"Chen, Z. W. Protective immune responses of major V\u03b32V\u03b42 T-cell subset in M. tuberculosis infection. Curr. \u00a0Opin. Immunol. 42, 105\u2013112 (2016).","journal-title":"Curr. Opin. Immunol."},{"key":"38_CR160","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.4049\/jimmunol.1602019","volume":"198","author":"A Qaqish","year":"2017","unstructured":"Qaqish, A. et al. Adoptive transfer of phosphoantigen-specific \u03b3\u03b4 T cell subset attenuates mycobacterium tuberculosis infection in nonhuman primates. J.\u00a0Immunol. 198, 4753\u20134763 (2017).","journal-title":"J. Immunol."},{"key":"38_CR161","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3389\/fimmu.2019.01124","volume":"10","author":"C Manickam","year":"2019","unstructured":"Manickam, C., Shah, S. V., Nohara, J., Ferrari, G. & Reeves, R. K. Monkeying around: using non-human primate models to study NK cell biology in HIV infections. Front. Immunol. 10, 1124 (2019).","journal-title":"Front. Immunol."},{"key":"38_CR162","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer 18, 407\u2013418 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"38_CR163","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","volume":"174","author":"KK Dijkstra","year":"2018","unstructured":"Dijkstra, K. K. et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174, 1586\u20131598 (2018).","journal-title":"Cell"},{"key":"38_CR164","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/d41586-018-06751-0","volume":"562","author":"H Ledford","year":"2018","unstructured":"Ledford, H., Else, H. & Warren, M. Cancer immunologists scoop medicine Nobel Prize. Nature 562, 20\u201321 (2018).","journal-title":"Nature"},{"key":"38_CR165","first-page":"657","volume":"5","author":"C Harly","year":"2014","unstructured":"Harly, C., Peigne, C. M. & Scotet, E. Molecules and mechanisms implicated in the peculiar antigenic activation process of human V\u03b39V\u03b42 T cells. Front. Immunol. 5, 657 (2014).","journal-title":"Front. Immunol."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41573-019-0038-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41573-019-0038-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41573-019-0038-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:44:56Z","timestamp":1684604696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-019-0038-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":165,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1038\/s41573-019-0038-z","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736565406.793573532","asserted-by":"object"}]},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"assertion":[{"value":"9 July 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D.M. is scientific adviser of American Gene Technologies; B.S.S. is a cofounder of Lymphact SA, a shareholder and scientific adviser of GammaDelta Therapeutics, and an inventor on patents dealing with DOT cells. J.K. is cofounder, shareholder and scientific adviser of GADETA and inventor on multiple patents dealing with gdTCR and their ligands, as well as with isolation techniques for engineered immune cells. Z.S. is an inventor of patents dealing with gdTCR and their ligands. I.P. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}